You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 6,686,168


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,686,168
Title: Cell surface display of proteins by recombinant host cells
Abstract:Methods and vectors are described for expressing recombinant proteins on the surface of host cells. These processes and compositions provide the basis for strategies to produce a fusion protein, comprising a membrane anchor that allows extracellular attachment of the fusion protein in a type II orientation.
Inventor(s): Lok; Si (Seattle, WA)
Assignee: ZymoGenetics, Inc. (Seattle, WA)
Application Number:09/704,090
Patent Claims:1. A method of selecting nucleic acid molecules that encode a member of a complementary/anti-complementary binding pair, comprising: (a) transfecting an expression vector into eukaryotic host cells to produce recombinant host cells, wherein the expression vector comprises: (i) a eukaryotic promoter, (ii) a nucleotide sequence encoding a type II signal anchor domain segment, and (iii) a gene, or gene fragment, that encodes the first member of a complementary/anti-complementary binding pair, wherein the expression vector comprises elements (i) to (iii) in a 5' to 3' order, wherein the gene, or gene fragment, resides in-frame with the nucleotide sequence that encodes the type II signal anchor domain, and wherein the nucleotide sequence that encodes the type II signal anchor domain segment is heterologous with respect to the gene, or gene fragment, (b) incubating the recombinant host cells under conditions and a time sufficient for expression of the first member of a complementary/anti-complementary binding pair on the surface of the recombinant cells, (c) exposing the recombinant cells to the second member of the complementary/anti-complementary binding pair, and (d) selecting recombinant cells that bind the second member of the complementary/anti-complementary binding pair.

2. The method of claim 1, wherein the gene, or gene fragment, comprises genomic DNA.

3. The method of claim 1, wherein the gene, or gene fragment, comprises cDNA.

4. The method of claim 1, wherein the expression vector further comprises a nucleotide sequence that encodes a spacer peptide, wherein the spacer peptide-encoding nucleotide sequence resides between the nucleotide sequence encoding the type II signal anchor domain segment and the gene, or gene fragment, that encodes the first member of a complementary/anti-complementary binding pair, and wherein the spacer peptide comprises at least ten amino acids.

5. The method of claim 1, wherein the expression vector further comprises a nucleotide sequence that encodes an affinity tag, wherein the affinity tag-encoding nucleotide sequence resides between the nucleotide sequence encoding the type II signal anchor domain segment and the gene, or gene fragment, that encodes the first member of a complementary/anti-complementary binding pair.

6. The method of claim 1, wherein the expression vector further comprises a nucleotide sequence that encodes an intron, wherein the intron-encoding nucleotide sequence resides between the promoter and the nucleotide sequence encoding the type II signal anchor domain segment.

7. The method of claim 1, wherein the complementary/anti-complementary binding pair is a receptor/ligand pair or an antibody/epitope pair.

8. The method of claim 1, wherein the second member of the complementary/anti-complementary binding pair is mobilized on a solid support.

9. The method of claim 1, wherein the second member of the complementary/anti-complementary binding pair is detectably labeled.

10. The method of claim 1 wherein the eukaryotic host cells are mammalian cells.

11. A method of selecting nucleic acid molecules that encode a member of a complementary/anti-complementary binding pair, comprising: (a) incubating recombinant eukaryotic host cells that comprise an expression vector comprising: (i) a eukaryotic promoter, (ii) a nucleotide sequence that encodes an intron, (iii) a nucleotide sequence encoding a type II signal anchor domain segment, and (iv) a nucleotide sequence that encodes an affinity tag, (v) a gene, or gene fragment, that encodes the first member of a complementary/anti-complementary binding pair, wherein the expression vector comprises elements (i) to (v) in a 5' to 3' order, wherein the gene, or gene fragment, resides in-frame with the nucleotide sequence that encodes the type II signal anchor domain, and wherein the nucleotide sequence that encodes the type II signal anchor domain segment is heterologous with respect to the gene, or gene fragment, and wherein the recombinant host cells are incubated under conditions and a time sufficient for expression of the first member of a complementary/anti-complementary binding pair on the surface of the recombinant cells, (b) exposing the recombinant cells to the second member of the complementary/anti-complementary binding pair, and (c) selecting recombinant cells that bind the second member of the complementary/anti-complementary binding pair.

12. The method of claim 11, wherein the complementary/anti-complementary binding pair is a receptor/ligand pair or an antibody/epitope pair.

13. The method of claim 11 wherein the recombinant eukaryotic host cells are mammalian cells.

14. A method of selecting cells that express a polypeptide of interest from among a collection of cells, comprising: (a) incubating a collection of recombinant eukaryotic host cells transfected with a plurality of expression vectors, wherein said plurality of expression vectors comprises a plurality of genes or gene fragments encoding polypeptides and wherein each of said expression vectors comprises: (i) a eukaryotic promoter, (ii) a nucleotide sequence encoding a type II signal anchor domain segment, and (iii) one of said plurality of genes or gene fragments, wherein each of said expression vectors comprises elements (i) to (iii) in a 5' to 3' order, wherein the one of said plurality of genes or gene fragments resides in-frame with the nucleotide sequence that encodes the type II signal anchor domain, and wherein the nucleotide sequence that encodes the type II signal anchor domain segment is heterologous with respect to the one of said plurality of genes or gene fragments, whereby said plurality of genes or gene fragments are expressed by said cells and whereby said polypeptides are produced as cell-surface polypeptides on said cells, and (b) selecting recombinant host cells that produce the polypeptide of interest.

15. The method of claim 14, wherein the one of said plurality of genes or gene fragments comprises genomic DNA.

16. The method of claim 14, wherein the one of said plurality of genes or gene fragments comprises cDNA.

17. The method of claim 14, wherein the expression vector further comprises a nucleotide sequence that encodes a spacer peptide, wherein the spacer peptide-encoding nucleotide sequence resides between the nucleotide sequence encoding the type II signal anchor domain segment and the gene or gene fragment, and wherein the spacer peptide comprises at least ten amino acids.

18. The method of claim 14, wherein the expression vector further comprises a nucleotide sequence that encodes an affinity tag, wherein the affinity tag-encoding nucleotide sequence resides between the nucleotide sequence encoding the type II signal anchor domain segment and the gene or gene fragment.

19. The method of claim 14, wherein the expression vector further comprises a nucleotide sequence that encodes an intron, wherein the intron-encoding nucleotide sequence resides between the promoter and the nucleotide sequence encoding the type II signal anchor domain segment.

20. The method of claim 14 wherein the recombinant eukaryotic host cells are mammalian cells.

21. A method of selecting a gene or gene fragment that encodes a polypeptide of interest, comprising: (a) transfecting eukaryotic host cells with a plurality of expression vectors to produce a collection of recombinant host cells, wherein said plurality of expression vectors comprises a plurality of genes or gene fragments encoding polypeptides, and wherein each of the expression vectors comprises: (i) a eukaryotic promoter, (ii) a nucleotide sequence encoding a type II signal anchor domain segment, and (iii) one of said plurality of genes or gene fragments, wherein each of the expression vectors comprises elements (i) to (iii) in a 5' to 3' order, wherein the one of said plurality of genes or gene fragments resides in-frame with the nucleotide sequence that encodes the type II signal anchor domain, and wherein the nucleotide sequence that encodes the type II signal anchor domain segment is heterologous with respect to the one of said plurality of genes or gene fragments; (b) incubating the collection of recombinant host cells, whereby each of said cells displays a polypeptide encoded by the one of said plurality of genes or gene fragments; and (c) selecting recombinant host cells that display the polypeptide of interest on the cell surface.

22. The method of claim 21, wherein the one of said plurality of genes or gene fragments comprises cDNA.

23. The method of claim 21, wherein the one of said plurality of genes or gene fragments comprises genomic DNA.

24. The method of claim 21 wherein the eukaryotic host cells are mammalian cells.

25. A method of selecting nucleic acid molecules that encode a polypeptide of interest, comprising: (a) incubating recombinant eukaryotic host cells that comprise an expression vector comprising: (i) a eukaryotic promoter, (ii) a nucleotide sequence that encodes an intron, (iii) a nucleotide sequence encoding a type II signal anchor domain segment, (iv) a nucleotide sequence that encodes an affinity tag, (v) a nucleotide sequence that encodes the polypeptide of interest, and wherein the expression vector comprises elements (i) to (v) in a 5' to 3' order, wherein the nucleotide sequence that encodes a polypeptide of interest resides in-frame with the nucleotide sequence that encodes the type II signal anchor domain, and wherein the nucleotide sequence that encodes the type II signal anchor domain segment is heterologous with respect to the nucleotide sequence that encodes the polypeptide of interest, and wherein the recombinant host cells are incubated under conditions and a time sufficient for expression of the nucleotide sequence that encodes the polypeptide of interest, and (b) selecting recombinant host cells that comprise the polypeptide of interest on the cell surface.

26. The method of claim 25 wherein the recombinant eukaryotic host cells are mammalian cells.

27. A method of selecting nucleic acid molecules that encode a member of a complementary/anti-complementary binding pair, comprising: (a) incubating recombinant eukaryotic host cells that comprise an expression vector comprising: (i) a eukaryotic promoter, (ii) a nucleotide sequence encoding a type II signal anchor domain segment, and (iii) a gene, or gene fragment, that encodes the first member of a complementary/anti-complementary binding pair, wherein the expression vector comprises elements (i) to (iii) in a 5' to 3' order, wherein the gene, or gene fragment, resides in-frame with the nucleotide sequence that encodes the type II signal anchor domain, and wherein the nucleotide sequence that encodes the type II signal anchor domain segment is heterologous with respect to the gene, or gene fragment, and wherein the recombinant host cells are incubated under conditions and a time sufficient for expression of the first member of a complementary/anti-complementary binding pair on the surface of the recombinant cells, (b) exposing the recombinant cells to the second member of the complementary/anti-complementary binding pair, and (c) selecting recombinant cells that bind the second member of the complementary/anti-complementary binding pair.

28. The method of claim 27, wherein the gene, or gene fragment, comprises genomic DNA.

29. The method of claim 27, wherein the gene, or gene fragment, comprises cDNA.

30. The method of claim 27, wherein the expression vector further comprises a nucleotide sequence that encodes a spacer peptide, wherein the spacer peptide-encoding nucleotide sequence resides between the nucleotide sequence encoding the type II signal anchor domain segment and the gene, or gene fragment, that encodes the first member of a complementary/anti-complementary binding pair, and wherein the spacer peptide comprises at least ten amino acids.

31. The method of claim 27, wherein the expression vector further comprises a nucleotide sequence that encodes an affinity tag, wherein the affinity tag-encoding nucleotide sequence resides between the nucleotide sequence encoding the type II signal anchor domain segment and the gene, or gene fragment, that encodes the first member of a complementary/anti-complementary binding pair.

32. The method of claim 27, wherein the expression vector further comprises a nucleotide sequence that encodes an intron, wherein the intron-encoding nucleotide sequence resides between the promoter and the nucleotide sequence encoding the type II signal anchor domain segment.

33. The method of claim 27, wherein the complementary/anti-complementary binding pair is a receptor/ligand pair or an antibody/epitope pair.

34. The method of claim 27, wherein the second member of the complementary/anti-complementary binding pair is bound to a solid support.

35. The method of claim 27, wherein the second member of the complementary/anti-complementary binding pair is detectably labeled.

36. The method of claim 27 wherein the recombinant eukaryotic host cells are mammalian cells.

Details for Patent 6,686,168

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2019-11-04
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2019-11-04
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2019-11-04
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.